Matrilins: structure, expression and function  by Segat, D. et al.
Osteoarthritis and Cartilage (2001) 9, Supplement A, S29–S35
© 2001 OsteoArthritis Research Society International 1063–4584/01/0A0S29+07 $35.00/0
doi:10.1053/joca.2001.0441, available online at http://www.idealibrary.com onMatrilins: structure, expression and function
D. Segat, M. Paulsson and N. Smyth
Institute for Biochemistry, Medical Faculty, University of Cologne, Cologne, GermanyIntroduction
The matrilins are a family of non-collagenous extracellular
matrix proteins grouped by their similar structure. As with
many matrix proteins matrilins are made up of multiple
modules (Fig. 1). The prototype of the family is matrilin-1,
previously called cartilage matrix protein (CMP)1 or the
148 kDa cartilage protein2. Since 1996 three further
members have been found: matrilin-23, -34,5 and -46.
Alignment of the matrilin sequences shows a strong simi-
larity between all the proteins. The matrilins can exist as
homooligomers due to the presence of a C-terminal heptad
repeat domain which forms an -helical coiled-coil3,7.
Matrilin-1 and -3 can also form heterooligomers8 of variable
stoichiometry9. The pattern of tissue expression varies for
each of the members and the matrilins may be used as
markers for cellular differentiation.EVOLUTIONARY ASPECTS
The matrilin monomer is characterized by the presence
of von Willebrand factor A (vWFA)1 domains and by epi-
dermal growth factor-like (EGF) repeats. The vWFA
domains can be divided into two groups, on the basis of
homology between the different matrilins, with the
N-terminal vWFA1 domain in one group and the C-terminal
vWFA2 domain within a second. This suggests that the
branch point in matrilin evolution occurred after duplication
of the vWFA domains. Both vWFA domains of matrilin-2 are
similar to their counterparts in matrilin-4, while the vWFA
domain of matrilin-3 is more related to the vWFA1 of
matrilin-1, suggesting a separate ancestor for matrilin-1
and -3 and for matrilin-2 and -4 (Fig. 210). This is also
supported by their different expression patterns (see
below). Each single EGFrepeat is coded by a single exon,
suggesting evolution by single or multiple exon duplication.
The coiled-coil domains have the lowest similarity which is
not surprising given they have low natural selection con-
straints, requiring only amino acids of certain character in
set positions. The final intron has a non-consensus splice
site sequence (AT-AC as opposed to the more common
GT-AG) which is conserved through all known matrilin
genomic sequences10. As this splice site occurs between
exons forming the coiled-coil region it is evidence that the
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Matrilin-1 is the best studied matrilin and will therefore be
the focus of the present review. It was first identified as a ca
200 kDa protein associated with aggrecan that had been
purified from adult bovine trachea under non-dissociative
conditions1. Upon reduction this product appeared as a
60 kDa band on SDS-PAGE. The same protein could be
extracted with higher yields by the use of 5 M guanidinium
HCl11. By analytical ultracentrifugation of the purified
matrilin-1 its molecular mass could be determined more
exactly to 148 kDa for the trimer and 52 kDa for the
monomeric subunit.
The primary structure of matrilin-1 has been deduced
from the cDNA sequence of chicken12,13, human14 and
mouse15. It is highly conserved between species with 79%
of all amino acid residues and all 12 cysteines being
identical between chicken and man14. The deduced struc-
ture consists of two vWFA domains, each of 190 amino
acids and both flanked, as in all the matrilin vWFA domains,
N- and C-terminally by cysteines which form an intrachain
disulphide bridge. The vWFA domains of matrilin-1 are
interconnected by a single EGF domain. C-terminally a
region of five heptad repeats is found which forms an
-helical coiled-coil16, directly N-terminal to this are two
cysteine residues separated by a single amino acid. These
form interchain disulphide bonds which stabilize the oligo-
meric molecule17,18. A potential N-glycosylation site is
present in the first vWFA domain and is used as shown by
chemical analysis11.
The human matrilin-1 gene is on chromosome 1 and
localized to p3514 while the murine gene is found on
chromosome 4, close to but distinct from the mapped site of
the cn achondroplasia locus15. The genomic structure for
matrilin-1 has been described for the chicken13, human14
and mouse19. In all cases the genes conserve their intron
and exon borders and consist of eight exons. Each of the
vWFA domains are encoded by two exons separated by an
intron. In both cases the cysteines flanking the vWFA are
close to the 5′and 3′ ends of the exons, respectively,
suggesting an evolutionary domain duplication after
insertion of the intron.
Matrilin-1 gene regulation has been studied in the
chicken and has been shown to be highly complex,
controlled by at least five cis-acting chondrocyte specific
and non-specific elements13. There is a minimal region
of promoter activity containing CAT- and TATA-like
sequences. A chondrocyte-specific enhancer region is
present in intron 1. Interestingly, this enhancer has been
shown to have a repressor effect in fibroblasts. Directly
before the TATA-box, two silencer areas (SI and SII) are
present inhibiting gene expression both in chondrocytes
S30 D. Segat et al.: Matrilins: structure, expression and functionFig. 1. Domain structure of the four members of the matrilin family in mouse (modified from Ref. 10). The upper part shows the basic
structures and the lower part highlights the variability in matrilin-4 structure resulting from alternative splicing.Fig. 2. Evolution of the matrilin genes (modified from Ref. 10).and fibroblasts20,21. Finally there is a chondrocyte specific
repressor region far (6–11 kb) upstream of the TATA box
which appears to regulate the expression of matrilin-1
during chondrocyte differentiation in the growth plate22.
Together these elements give tightly regulated transcription
of the gene in each tissue and developmental stage.
Initial studies on the expression of matrilin-1, based on
the use of a radioimmunoassay of tissue extracts, showedthat matrilin-1 is not ubiquitous in cartilages2 and that its
expression level alters with time23. In the adult bovine,
matrilin-1 is present in many hyaline cartilages with the
highest amounts in the tracheal rings but also appreciably
present in the nasal and xiphisternal cartilage. It is also
found, but at much lower levels in the auricular (elastic
cartilage) and epiphyseal cartilages while it is absent from
the articular cartilage and from the fibrocartilage of the
vertebral disc and the nucleus pulposus2.
In limb development matrilin-1, as other cartilage
proteins, has a highly organized expression pattern. It has
been shown in the chick, by in situ hybridization, that
collagen II is first expressed (Hamburger stage 23, 3.75
days) followed successively by link protein and aggrecan
(stage 25, 4.5 days)24 and matrilin-1 (stage 26,
5 days)22,25. Collagen VI is expressed in the early stages
of differentiation, but only transiently26. This shows that
matrilin-1 appears after the cartilage formation has overtly
begun. It is initially restricted to the more proximal area of
the developing limb, prior to becoming homogeneous over
the whole anlage.
Zonal distribution of expression occurs with the onset of
ossification as the growth plate forms. Immunohistochemi-
cal analysis of chick embryo limbs shows matrilin-1 present
in the lower proliferative zone and in the immediately
adjacent hypertrophic cartilage of the growth plate27. One
model for growth plate cell differentiation uses matrilin-1 as
Osteoarthritis and Cartilage Vol. 9 Suppl. A S31Fig. 3. Expression of mRNA for chondrocyte differentiation markers
in the growth plate. Matrilin-1 serves as a marker for the maturation
step between proliferative and hypertrophic chondrocytes.
Fig. 4. The structure of matrilin-1 homotrimers. The model is based
on a combination of sequence interpretation and electron
microscopy16.a marker for chondrocyte maturation (Fig. 3). In situ hybrid-
ization evidence shows that cells expressing matrilin-1
occur lower in the growth plate than those staining with
BrdU and so are no longer actively proliferating28. How-
ever, these cells are not yet expressing the message for
collagen X which is a known marker for hypertrophic
chondrocytes29. In organ cultures of proliferating chick
chondrocytes, the cells differentiate towards the hyper-
trophic state and the onset of matrilin-1 expression
coincides with the ‘reduction in proliferation’28. Similar
results have been described for matrilin-1 expression in
man where in situ hybridization showed initial widespread
expression in the bone anlagen first seen in 7-week
fetuses. By 10 weeks endochondral ossification has begun
with collagen II and matrilin-1 expressed in the lower
proliferative and upper hypertrophic zone. Matrilin-1
expression as in the chick was absent from the collagen X
expressing areas of the lower hypertrophic and calcified
epiphysis30.
In man the development of synovial joints starts at 8
weeks in the distal femur. Initially matrilin-1 and collagen II
are expressed by chondrocytes at the presumptive articular
surface, while collagen I expression occurs in articular
perichondrium. Matrilin-1 expression is lost by 9 weeks
from the chondrocytes at what will be the load bearing
surface, but it continues deeper in the cartilage and at
the periphery of the joint30. In the mouse it has been
shown that the loss of matrilin-1 expression precedes the
formation of the joint cleft15.
That matrilin-1 is seen in some but not all hyaline
cartilages has led to the suggestion that in certain tissues
chondrocyte differentiation has become halted in a non-
proliferative stage where the cells are similar to the ‘so
called’ mature chondrocyte of the growth plate and
show matrilin-1 expression throughout life (e.g. trachea).
Possibly this stage can be initiated in other non-matrilin
expressing chondrocytes in tissues undergoing patho-
logical changes. High matrilin-1 serum levels have been
seen by radioimmuoassay in rheumatoid arthritis patients31
and this was initially suspected to be a sign of a wider
pathology affecting non-articular cartilage such as that
seen in polychondritis31,32. However, more recent immuno-
histological studies have shown that the numbers of
articular chondrocytes expressing matrilin-1 increases from
less than 5% in the normal controls to over 40% and 60% in
osteoarthritic and rheumatoid arthritis patients respect-
ively33 suggesting that matrilin-1 expression can be recom-
menced in certain chondrocytes. Further it raises the
possibility of serum levels of matrilin-1 being used as a
marker for cartilage pathology33.Matrilin-1 expression has also been detected in non-
cartilaginous tissues. It has been reported in bovine tendon
where it is presumably expressed by the fibroblasts of
the dense connective tissue34, as it is not produced by
embryonic chick skin fibroblasts35. The eye expresses a
number of cartilage associated proteins such as link
protein, collagen II, and aggrecan as well as matrilin-136. In
man matrilin-1 mRNA expression was located in the human
embryonic retina30 and the protein has been shown, by
immunohistochemistry, to be present in the chick cornea,
sclera and lens capsule from embryonic day 838 presum-
ably diffusing to these sites from the retina. A transient
expression of matrilin-1 occurs in the embryonal mouse
heart between days 9.5 and 14.5 post conceptum37.
Bovine tracheal matrilin-1 isolated upon guanidinum HCl
extraction appeared as a reducible subunit trimer11. While
sequence analysis showed that the C-terminal contained a
potential coiled-coil area, it was not until purification under
native conditions that the molecule could be shown as a
homotrimer by electron microscopy after rotary shadowing
and negative staining16. The trimer has a compact struc-
ture of three ellipsoids assembled together by the
C-terminal domain (Fig. 4) and its form is maintained after
reduction under non-denaturing conditions16.
The C-terminal polymerization domain consisting of five
heptad repeats was produced as a synthetic peptide and
shown to form highly stable coiled-coil -helical trimers38.
The two cysteine residues placed directly N-terminal to the
heptad repeats form interchain disulphide bonds but do not
play any role in the production of the trimer. They do,
however, act to stabilize it and may alter the flexibility of
oligomeric molecule. A similar structure with disulphide
bonds stabilizing a coiled-coil also occurs in fibrinogen,
tenascin, thrombospondins and laminin. The structure of
the coiled-coil has been solved by NMR which showed how
the two cysteines form a ring of three disulphide bridges
capping the coiled-coil39.
Matrilin-1 was first isolated in an attempt to find proteins
binding to cartilage proteoglycans under non-denaturing
conditions1. In fact, in later work the interactions of
matrilin-1 and aggrecan have been shown to be of a
number of different types40. One pool of matrilin-1 can be
extracted from the tissue by EDTA suggesting weak
divalent cation mediated interactions with other tissue
proteins. A second pool shows a very strong but non-
covalent binding to aggrecan which can overcome by
treating the proteoglycans with strong chaotrophic agents
such as 7 M urea, 4 M guanidinium chloride or 2% SDS. The
last pool cannot be dissociated from proteoglycans by the
S32 D. Segat et al.: Matrilins: structure, expression and functionabove means and is presumably covalently crosslinked to
the aggrecan core protein. Matrilin-1 subunits can be
released from this pool upon reduction but probably this
results from the breakage of the intermolecular disulphide
bonds in the matrilin trimer, as only two-thirds of the protein
is released. The third remaining upon the proteoglycans is
presumably linked by non-reducible bonds40. The amount
of matrilin-1 covalently bound to proteoglycans increases
with age40. The interaction sites for matrilin-1 on aggrecan
have been identified by electron microscopy after rotary
shadowing. Labelling of the matrilin-1/aggrecan complex
with a matrilin-1 antibody shows matrilin-1 as globules
found at specific sites on the chondroitin-sulphate-carrying
E2 domain of the core protein. With age there is an
increasing proportion of the binding sites occupied by
matrilin-1 and the greater use of sites more C-terminal
within the E2 domain.
In chick chondrocyte cultures, matrilin-1 is present in a
network associated with collagen II fibrils41. Later work
showed that matrilin-1 is found in two types of filaments35.
In the absence of ascorbate, collagen fibrils do not form, yet
the matrilin-1 occurs as a network of small filaments over
and around the cells, while in the presence of ascorbate the
matrilin-1 also occurs in fibres with collagen II that are
much thicker and extend out from the cell colonies.
Infection with a matrilin-1 retrovirus gave similar results.
Collagen I producing fibroblasts formed a fine meshwork
containing matrilin-1, while chick chondrocytes incorpor-
ated the myc tagged recombinant protein within thicker
collagen II-containing fibres. A mutated construct without
the C-terminal coiled-coil was incorporated into networks in
a similar way. While a construct containing only the vWFA2
domain and the coiled-coil, could trimerize and form all
possible heterotrimeric forms with the wild type matrilin-1 in
chondrocytes, it was unable to produce fibrils in infected
fibroblasts. Further it appeared to inhibit the formation of
collagen II- and matrilin-1-containing fibres by chick
chondrocytes35. Deletion of the vWFA2 domain results in
incomplete trimerization of matrilin-1, while point mutations
in the metal ion dependent adhesion sites (MIDAS) inter-
fere with matrilin-1 network formation42. These data sug-
gest that the two vWFA domains are essential for matrilin-1
function, but also that they may act in a different manner,
possibly due to physical constraints imposed upon the
second vWFA due to its close position to the disulphide
bonds at the head of the coiled-coil35,42.
Self-interaction of matrilin-1 was demonstrated in
guanidinium HCl extracts from bovine tracheal cartilage
which were fractionated using a hydrophobic chroma-
tography purification step upon a octyl-Sepharose CL-4B
column. Here SDS-PAGE followed by detection with a
matrilin-1 antibody showed both the trimer and additional
higher mass matrilin-1, comprising 25% of the extracted
protein. The reduced protein appeared as a single band
corresponding to the matrilin-1 monomer. This suggests
either that other forms of matrilin-1 oligomers exist or that
matrilin-1 can by disulphide-exchange produce higher
order products43.
Recently a new form of matrilin-1 oligomer was discov-
ered. After extraction from bovine epiphysis, a matrilin-1
immunoreactive band was seen running unreduced at
240 kDa in SDS-PAGE. Upon reduction, two close bands
at 60 kDa were identified. N-terminal sequence analysis
gave distinct sequences, one of which was identical to
the bovine matrilin-1 sequence, and the other novel. Tryptic
peptides of the new protein were then sequenced and
the bovine homologue of matrilin-3 identified. Hence itappears that matrilin-1 and -3 can form a disulphide linked
heterooligomer8.MATRILIN-2
In a search for proteins homologous to matrilin-1, a
mouse epiphyseal cDNA library was screened at low
stringency using a probe for chicken matrilin-1 and a novel
gene was identified3. Matrilin-2, as it was later named, is a
protein with a predicted Mr of 104 kDa formed of 956 amino
acids. It has a similar domain structure to matrilin-1 con-
sisting of a putative signal peptide, two vWFA-like modules
separated by ten EGF repeats (Fig. 1). It has a unique
sequence of 75 amino acids between the second vWFA-
like domain and the C-terminal oligomerization unit.
N-terminally it has a group of positively charged amino
acids preceeding the first vWFA-like domain. The amino
acid sequence contains two consensus sequences for
potential N-glycosylation, one localized at the end of the
vWFA2 and the other in the segment directly preceding the
coiled-coil domain3. The primary structure of human
matrilin-2 was recently determined44. It shows 93% amino
acid identity with the mouse protein and conservation of all
features of the domain structure.
A synthetic peptide based on the matrilin-2 heptad
repeat domain has been shown to assemble into a homo-
trimer similar to that seen for matrilin-1, although dimers,
tetramers and pentamers also occur45. Similarly SDS-
PAGE analysis and electron microscopy studies of recom-
binant matrilin-2 has shown mono-, di-, tri- and tetrameric
forms with Mr values estimated by SDS-PAGE ranging up
to 500 kDa. These are also produced by various cell lines
as well as occurring in extracts from murine skin and
uterus46. The subunits are connected at a single point in
the C-terminal domain and generally form loops with a
diameter of 8 nm although in some cases the subunits
appear in an extended form46. The loops are probably
formed by intramolecular interactions of the vWFA
domains. Whether the heterogeneity is due to the initial
formation of oligomers with differing numbers of matrilin-2
molecules or whether it occurs later due to cleavage of
some of the strands at a site close to the coiled-coil is not
yet known46. RT-PCR from endothelial and chondrosar-
coma cell lines has shown alternative splicing involving the
unique region directly before the coiled-coil. The signifi-
cance of this splice variant and whether it is expressed
in vivo is unknown46. The matrilin-2 gene is transcribed in a
wide variety of organs such as calvaria, uterus, heart and
brain and its mRNA is detected in fibroblasts and osteoblast
cell lines. While in situ hybridization studies confirmed the
above they also showed expression in epithelial cells and
all forms of muscle3,46. Immunohistochemical analysis in
mice have shown the protein abundant in tendon, ligament
and perichondrium. It is further expressed but in lower
amounts in loose connective tissues, for example in the
papillary layer of dermis and the spleen trabeculae46. In
cartilage it is found in the proliferating and hypertrophic
zones of the epiphysis as well as in the elastic cartilage of
the ear and in the fibrocartilage in the anulus fibrous of the
intervertebral disc46. Matrilin-2 was found also in the dura
and pia mater of the brain and in the spinal cord as well as
the perineurium of the peripheral nerves. It is present in the
blood vessel wall. In many tissues it appears to be in part
associated with the basement membrane. Immunofluor-
escence microscopy of cultures of smooth muscle cells
showed matrilin-2 in an extensive, extracellular fibrillar
network.
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An EST clone from human lung identified by a data base
homology search had a high sequence identity to the
vWFA1 domains of matrilin-1 and -2. The full length cDNA
was then obtained from a mouse lung library4. cDNA
sequences have recently also been described from
chicken5 and man47. The gene for matrilin-3 is localized to
chromosome 2 in the region p24-23 in man47 and to the
proximal end of chromosome 12, linked to the genes Apob,
Dtnb and Kif3c, in mouse48.
The protein precursor consists of a signal peptide, a
short positively charged sequence, a single vWFA-like
domain followed by four EGF modules and a C-terminal
coiled-coil -helical domain (Fig. 1). It is the smallest
member of the family with a predicted Mr of 49 kDa.
Matrilin-3 has high similarity across species with 61%
amino acid identity between human and chicken. The
structure is conserved between species with the exception
of one additional amino acid in each of the four EGF
domains, between the third and fourth cysteine residues in
the human and mouse protein, when compared with the
chicken. By sequence homology matrilin-3 is most closely
related to matrilin-1, but it has lost the vWFA2 found in
all other matrilins4. The recombinant protein occurs in all
possible forms from monomer to tetramer9.
Northern hybridization in the mouse shows matrilin-3
mRNA in many cartilaginous tissues including the articular
cartilage and very weakly in trachea, as well as sternum
and femur4. Matrilin-3 was absent from all non-skeletal
tissues examined and its expression, while similar to that of
matrilin-1, is wider spread through the cartilage and further
it is expressed by osteoblasts9. While both matrilin-1 and -3
are found in the mature trachea, matrilin-3 is at far lower
levels8. In situ hybridization shows that the expression of
matrilin-3 colocalizes with that for collagen type II in
chicken stemum and that matrilin-3 and collagen II are
transiently expressed by dedifferentiating chondrocytes in
culture47. While in most cases matrilin-3 is present as a
homooligomer, that isolated from epiphyseal bovine
cartilage forms heterotetrameric oligomers with matrilin-18.
While the intial studies suggested a two to two stoi-
chiometry8, more recent work has shown the presence of
heterotetramers of different stoichiometry as well as
heterotrimers9. Like matrilin-1 and matrilin-2, matrilin-3
forms extracellular networks surrounding cells. Some of the
fibrillar structures contain also collagen as they are not
seen in the absence of ascorbate. Interestingly, matrilin-3
containing filaments connect neighbouring cells, possibly
providing spatial information to these9.MATRILIN-4
A fourth member of the matrilin family was identified from
a EST cDNA clone of a 19-day-old mouse embryo. To date
mouse6 and human49 cDNA has been sequenced. The
cDNA for mouse matrilin-4 encodes for a putative signal
peptide, two vWFA-like domains linked by EGF repeats and
an oligomerization domain (Fig. 1). The mature protein has
a Mr of 66 kDa. N-glycosylation sites are present in the
vWFA1 domain and in the third EGF-like repeat. Matrilin-4
assembles into trimers, but extensive proteolysis occurs in
tissues and in cell culture medium yielding also smaller
forms7. Extensive alternative splicing has been shown for
matrilin-46,49. As with the other matrilins the exon-intron
structure closely aligns with the borders of the individualdomains and, hence, alternative splicing leads to the loss of
whole domains. Initial studies on the murine cDNA showed
that there were two forms of the transcript, with one form
lacking the vWFA1 domain, giving a potential protein of
45 kDa. This splice form appears rarely expressed and
developmentally regulated6.
Human matrilin-4 shares an amino acid similarity of 91%
to the murine protein6. The gene consists of ten exons and
is present on chromosome 20 localized to q13.1-2. Due to
a GT-AT mutation at the 5′ splice donor site of intron C the
first EGF is spliced out and exon 4 is only present as a
pseudo exon. Like murine matrilin-4, the human form is
alternatively spliced49. This splicing is, however, of quite a
different nature. RT-PCR analysis showed three different
splice forms. Unlike in the mouse they all contain both
vWFA domains, but they differ in having one, two or three
EGF-repeats.
Matrilin-4 is widely expressed. In the mouse its highest
expression is in the lung, with signals also being found by
Northern hybridization in brain, kidney, heart and sternum6.
Immunohistochemistry on sections of mouse tissues
showed a broad expression in dense and loose connective
tissue, bone, cartilage, central and peripheral nervous
system and in association with basement membranes7.
The differentially spliced mRNA form lacking the vWFA1
domain, is seen in Northern blots of lung and brain and has
by RT-PCR been shown present in kidney, sternum and
heart. The expression of this shorter transcript was found in
the adult mouse (50 days), but not in 19.5 day embryos or
in animals up to 3 weeks of age. In man, a soft tissue
expression has been detected, with matrilin-4 mRNA being
present in adult lung and placenta as well as being
expressed by the WI-26 fibroblast cell line and 293 human
embryonic kidney cells. RT-PCR showed that all three of
the splice forms could be found in these tissue or cells
types, but the two longer forms predominated49.PERSPECTIVES
The mutliple interactions of matrilins indicate that they
may act as adapter proteins in the extracellular matrix,
mediating interactions between collagens and proteo-
glycans and possibly also with other tissue components.
Indeed, a recent report suggests that matrilin-1 may bind to
cells via the 11 integrin50. In this regard it is surprising
that abolished matrilin-1 expression, achieved by gene
targeting in the mouse, does not lead to a clear pheno-
type51, even though slight alterations in type II collagen
fibrillogenesis and fibril organization have been reported52.
A possible explanation is redundancy among matrilin family
members where matrilin-1 and -3 often occur in the same
tissue at the same time. The matrilins as a family are
almost ubiquitous, with one family member or another
occuring in almost every form of connective tissue matrix.
However, the genes coding for the individual members of
the family are under strict temporal and spatial regulation
with sometimes separate and sometimes common sites
of expression. This taken together with the potential for
alternative splicing and ability to form heterooligomers
suggest a high degree of versatility.
It is likely that major functions of matrilins are related to
their ability to form filaments and to associate with collagen
fibrils and we expect them to influence the mechanical
properties of tissues. In the case of cartilage this possibility
is highlighted by presence of matrilin-1 in most cartilages,
but not in the weight-bearing parts of the articular carti-
lage2,34. The de novo expression of matrilin-1 in arthritic
S34 D. Segat et al.: Matrilins: structure, expression and functionchondrocytes33 points to the usefulness of matrilins as
markers for chondrocyte differentiation.Acknowledgments
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